Co-Diagnostics (CODX) to Sell 3.3M Shares at $3.08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Pinterest CFO resigns, interim replacement named
Co-Diagnostics Announces $10.2 Million Registered Direct Offering Priced At-the-Market
February 11, 2020 8:00 AM ESTSALT LAKE CITY--(BUSINESS WIRE)-- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has entered into definitive agreements with institutional investors for the purchase of 3,324,676 shares of its common stock, at a purchase price per share of $3.08, in a registered direct offering priced at-the-marked under the Nasdaq rules. The closing of the offering is expected to occur on or about February 13, 2020, subject to the satisfaction of customary closing conditions.
H.C. Wainwright & Co. is... More
